Target intelligence / Profile preview

Tumor-Specific Neoantigens (derived from mutated proteins) (TSN)

Target: TSN
Molecular classification: Peptide, Protein fragment, Antigen

Overview

Tumor-specific neoantigens are novel peptide sequences generated by somatic mutations in tumor cells. These mutated proteins produce unique antigens that are not present in normal tissues. As a result, they can be recognized as "non-self" by the immune system, making them attractive targets for cancer immunotherapy. Mutant EGFR is an example of a protein that can produce neoantigens.

Other names: NeoantigensMutated Tumor AntigensTumor Mutation-Associated Neoantigens (TMAs)Personalized Tumor Antigens

Mechanism of action

Neoantigens are presented on MHC molecules and activate T-cells, leading to tumor cell lysis or immune modulation.

Biological functions

T-cell activationImmune response inductionAntigen presentationTumor cell recognition

Disease associations

CancerImmunotherapy responseTumor development

Safety considerations

Potential for off-target effects (though minimized compared to shared tumor antigens)Autoimmunity (rare, but possible)Cytokine release syndrome (CRS) in adoptive cell therapyImmune-related adverse events (irAEs)

Interacting drugs

Personalized cancer vaccines

5 more in the full profile.

Biomarkers

Tumor mutational burden (TMB)Neoantigen loadTumor-infiltrating lymphocytes (TILs)MHC-neoantigen binding affinityT-cell receptor (TCR) repertoireMutant EGFR peptide sequences

Beyond the preview

Go deeper on Tumor-Specific Neoantigens (derived from mutated proteins) (TSN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor-Specific Neoantigens (derived from mutated proteins) (TSN).

Explore the full profile